Cargando…

Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population

Hypoglycemia and acute metabolic complications (AMCs; ketoacidosis, hyperosmolarity, and coma) are glycemic outcomes that have high cost and high morbidity; these outcomes must be taken into consideration when choosing initial second-line therapy after metformin. We conducted a retrospective cohort...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wallia, Amisha, O’Brien, Matthew J., Liss, David T., Kang, Raymond H., Cooper, Andrew J., Gilmer, Amy, Ackermann, Ronald T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240148/ https://www.ncbi.nlm.nih.gov/pubmed/34195559 http://dx.doi.org/10.1016/j.mayocpiqo.2021.02.008

Ejemplares similares

Correlates of second-line type 2 diabetes medication selection in the USA
por: Ackermann, Ronald T, et al.
Publicado: (2017)

Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
por: Wallia, Amisha, et al.
Publicado: (2023)

Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin
por: DeCarlo, Kristen, et al.
Publicado: (2022)

MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
por: Meloni, Seema T, et al.
Publicado: (2017)

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

Direct Cost of Parkinson's Disease: A Real-World Data Study of Second-Line Therapies
por: Gomez-Inhiesto, Elisa, et al.
Publicado: (2020)

PSUN330 Patients with Recurrent Hypoglycemia Encounters Across Chicago: Who are they?
por: Zhao, Lihui, et al.
Publicado: (2022)

Initial inhaler choice in COPD: real-world evidence
por: Jones, Thomas
Publicado: (2019)

Severe hyperglycemia and insulin resistance in patients with SARS-CoV-2 infection: a report of two cases
por: Affinati, Alison H., et al.
Publicado: (2021)

Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium
por: Schinzari, Giovanni, et al.
Publicado: (2018)

A real-world experience of second-line nivolumab in mesothelioma patients during the COVID-19 pandemic
por: Church, Matt, et al.
Publicado: (2021)

Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence
por: Cuker, Adam, et al.
Publicado: (2023)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features
por: Akturk, Halis Kaan, et al.
Publicado: (2021)

Dapagliflozin-Induced Acute-on-Chronic Liver Injury
por: Levine, Joshua A., et al.
Publicado: (2016)

Context-dependent choice and evaluation in real-world consumer behavior
por: Otto, A. Ross, et al.
Publicado: (2022)

Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira)
por: Zenari, Luciano, et al.
Publicado: (2020)

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
por: Koutsoukos, Konstantinos, et al.
Publicado: (2017)

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
por: Barzi, Afsaneh, et al.
Publicado: (2019)

Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Real‐world outcomes among patients with advanced or metastatic biliary tract cancers initiating second‐line treatment
por: Cosgrove, David P., et al.
Publicado: (2022)

Determination of Postprandial Glycemic Responses by Continuous Glucose Monitoring in a Real-World Setting
por: Röhling, Martin, et al.
Publicado: (2019)

Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology
por: Pinsker, Jordan E., et al.
Publicado: (2021)

Comment on Menke et al. Metals in Urine and Diabetes in U.S. Adults. Diabetes 2016;65:164–171
por: Wong, Winifred P., et al.
Publicado: (2016)

A Multi‐Biomarker Disease Activity Score and the Choice of Second‐Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure
por: Hambardzumyan, Karen, et al.
Publicado: (2017)

The Association of Dyslipidemia and Atherogenic Indices With Glycemic Control in Diabetic Dyslipidemia Patients: A Real-World Landscape
por: Bage, Isaac J, et al.
Publicado: (2023)

Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations
por: Jun, Soojin, et al.
Publicado: (2023)

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
por: Rittberg, Rebekah, et al.
Publicado: (2023)

Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
por: Gomez-Peralta, Fernando, et al.
Publicado: (2020)

Second premolar extraction: Not always a second choice
por: Mascarenhas, Rohan, et al.
Publicado: (2015)

Improvement in Insulin Sensitivity During Mifepristone Treatment of Cushing Syndrome:Early and Late Effects
por: Wallia, Amisha, et al.
Publicado: (2013)

Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps
por: Wallia, Amisha, et al.
Publicado: (2020)

Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
por: Garajová, Ingrid, et al.
Publicado: (2023)

The Role of Real-World Evidence to Support Treatment Choices in Malignant Pleural Mesothelioma
por: Wheatley-Price, Paul, et al.
Publicado: (2022)

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe
por: Becker, Jürgen C., et al.
Publicado: (2017)

Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
por: Abraham, Pranav, et al.
Publicado: (2020)

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
por: Dai, Wei Fang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tsbigbojfhbalbspo0io4ma96k